secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001213900-25-014281
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders elect Rosa, approve reverse stock split and 2025 equity plan at annual meeting.
--------------------------------------------------------------------------------

- David Rosa elected Class II director: 11,724,206 for, 381,677 against, 6,011,755 broker non-votes.
- Baker Tilly U.S., LLP ratified as auditor: 18,080,780 for, 7,381 against, 29,477 abstain.
- Reverse stock split approved (ratio 1-for-2 to 1-for-15): 16,176,833 for, 1,732,603 against.
- 2025 Equity Incentive Plan approved: 10,595,402 for, 1,473,888 against, 6,010,237 broker non-votes.
- Adjournment authorization approved: 16,811,725 for, 1,270,013 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025014281/0001213900-25-014281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025014281/ea0231253-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-014281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer